Physician profile
Bryan A Lucenta
NPI 1699886077
$10,156.60
in general payments reported to CMS, 2019-2025
25 companies · $835 in 2025
The $835 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,568 · 2020: $513 · 2021: $842 · 2022: $850 · 2023: $801 · 2024: $748 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $2,264.71 | 2019-2022 | |
| Medtronic Vascular, INC. | $1,404.16 | 2019-2020 | |
| Medtronic, INC. | $1,152.26 | 2022-2025 | Micra, Linq II, Compia Mri Quad Crt-D Surescan |
| W. L. Gore & Associates, INC. | $961.49 | 2019 | |
| Boston Scientific Corporation | $898.15 | 2019-2025 | General - Therapies, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $712.25 | 2019-2024 | Jot Dx, Gallant |
| Cook Incorporated | $496.23 | 2019 | |
| Cook Medical LLC | $336.22 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $296.66 | 2021-2025 | Lokelma, Farxiga |
| Abiomed | $294.80 | 2020-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.86 | 2021-2023 | Jardiance |
| Bard Peripheral Vascular, INC. | $196.00 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $156.64 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $145.15 | 2020-2024 | Lifevest |
| Kestra Medical Technology Services, INC. | $144.05 | 2023-2025 | Assure Wcd |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $120.02 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $72.95 | 2020-2022 | |
| Amarin Pharma, INC. | $60.15 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.01 | 2020-2023 | Camzyos |
| Pfizer INC. | $29.76 | 2025 | |
| Ge Healthcare | $24.71 | 2022 | |
| Biotronik INC. | $22.66 | 2019 | |
| Atricure, INC. | $20.55 | 2024 | |
| Inspire Medical Systems, INC. | $18.04 | 2025 | Inspire |
| Amgen INC. | $16.12 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Lucenta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.